Proventys is developing a suite of validated predictive tests (PDx) that help physicians individualize treatment decisions for patients at the point of care. The company’s lead PDx, delivered through the Proventys PDx Oncology™ system, is a predictive test to assess an adult cancer patient’s risk of developing chemotherapy-induced febrile neutropenia (FN), a costly, serious adverse event caused by the toxic effects of chemotherapy. 

The FN PDx uses a validated, multivariate statistical model to calculate a patient's numerical risk of developing FN during the first four cycles of chemotherapy.  Results from each risk assessment are presented to the clinician along with published clinical guidelines to help determine if prophylactic treatment with colony stimulating factor is appropriate for each specific patient.  Hundreds of thousands of patients initiating chemotherapy annually are at risk for FN and hospitalization.

FN PDx  is under review by the FDA (de novo); not available for sale in the United States.